Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA

Author:

Morabito Fortunato,Gentile Massimo,Ciolli Stefania,Petrucci Maria T.,Galimberti Sara,Mele Giuseppe,Casulli Antonio F.,Mannina Donato,Piro Eugenio,Pinotti Graziella,Palmieri Salvatore,Catalano Lucio,Callea Vincenzo,Offidani Massimo,Musto Pellegrino,Bringhen Sara,Baldini Luca,Tosi Patrizia,Di Raimondo Francesco,Boccadoro Mario,Palumbo Antonio,Cavo Michele

Publisher

Wiley

Subject

Hematology,General Medicine

Reference23 articles.

1. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341;Frankel;Clin Cancer Res,2000

2. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition;Cusack;Cancer Res,2001

3. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells;Hideshima;Cancer Res,2001

4. Renal failure in multiple myeloma. Pathogenesis and prognostic implications;Alexanian;Arch Intern Med,1990

5. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution;Blade;Arch Intern Med,1998

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3